Gujarat Themis Biosyn plans ₹1,000 crore QIP in 2026

What the board approved on June 6, 2026

Gujarat Themis Biosyn Limited’s Board of Directors has approved a fundraising programme of up to ₹1,000 crore. The plan involves raising capital through a Qualified Institutions Placement (QIP) and an additional preferential issue of equity shares to non-promoters, subject to approvals. The company indicated the QIP will be carried out in compliance with SEBI’s Issue of Capital and Disclosure Requirements (ICDR) Regulations, 2018.

The approval follows the company’s earlier intimation that the board would convene on June 6, 2026, to evaluate proposals for raising funds. The agenda included the issuance of equity shares or other securities through QIP, preferential allotment, or a combination of methods. The company has also flagged that the process will require necessary regulatory and statutory clearances.

Fundraising routes: QIP and preferential issue

Under the QIP route, the company may issue equity shares and or convertible securities, including instruments such as warrants, as indicated in the disclosures. The company has not yet specified the final instrument mix under the QIP. It also plans to raise additional funds via a preferential issue of equity shares to non-promoters, again subject to approvals.

Both routes typically involve multiple steps such as determining the issue size, deciding the securities to be issued, and complying with pricing and disclosure requirements under the ICDR framework. Gujarat Themis Biosyn has stated that the final details will be disclosed later.

Committee-led process and what is still undecided

Gujarat Themis Biosyn has formed a dedicated Fund-Raising Committee to manage the specifics of the fundraising initiative. According to the company’s disclosures, this committee will determine the number of securities, identify potential investors, and set the issue price for the preferential issue. The QIP details will also be finalised as part of this initiative.

At this stage, the company has not disclosed investor names, the final number of shares or convertible securities to be issued, or a definitive timeline. Investors have been advised to track company filings for updates on pricing, the number of securities, and the timeline for receiving regulatory and shareholder approvals.

Key dates flagged in company updates

The company’s disclosures refer to two key milestones: a board meeting intimation dated June 3, 2026, and the fundraising approval dated June 6, 2026. The June 3 filing highlighted that the board would consider issuing equity shares or securities through QIP or preferential allotment, or other permissible modes, in line with SEBI rules.

The June 6 board outcome marks the formal approval for a fundraising target of up to ₹1,000 crore. The company has positioned the next phase as a detailed structuring process through the committee and subsequent disclosures.

Stock price references around the announcement

The article data includes multiple price references for Gujarat Themis Biosyn. The share price is mentioned at ₹413.2 as of June 6, 2026. Separately, the stock is also cited as having moved down 4.74% from a previous close of ₹424.30, with the last traded price at ₹404.20.

These numbers indicate that the market was actively tracking the company around the fundraising developments, although the disclosures in the provided text do not attribute the price move to a specific driver.

Shareholder approvals: borrowing limits and inter-corporate investments

Alongside the fundraising plan, the article data notes that Gujarat Themis Biosyn shareholders approved special resolutions to increase borrowing limits and expand inter-corporate investment capabilities. Both resolutions passed with over 98% votes in favour, according to the text.

The stated outcome is greater financial flexibility. The disclosures do not provide revised borrowing limit figures in the same section, but they do frame the approvals as enabling broader financial capacity.

Financial snapshot: FY26 profit, income, and dividend proposal

The company reported FY26 net profit of ₹46.68 crore, down from ₹48.77 crore in the previous year. Over the same period, total income increased to ₹168.25 crore, based on the figures provided.

The board also recommended a final dividend of ₹0.67 per equity share, described as 67% of the face value of ₹1 each. The total dividend payout is stated at ₹7.30 crore and is subject to shareholder approval at the ensuing Annual General Meeting.

Other board decisions: cost auditor appointment

In the same set of board actions, the company approved the appointment of M/s Raja Dutta & Co., Cost Accountants, as the Cost Auditor for FY2026-27. The board also approved a proposal for a preferential issue of equity shares to non-promoters and constituted a Preferential Issue Committee to finalise terms and conditions, subject to necessary approvals.

Credit rating development cited in the data

The article data also references a CARE Ratings (CareEdge Ratings) action. CARE removed “Rating Watch with Developing Implications (RWD)” on the company’s bank facilities, reaffirmed ratings, and assigned a “Stable” outlook. This followed the company’s June 13, 2025, announcement on BSE regarding the withdrawal of an amalgamation scheme of Gujarat Themis Biosyn with Themis Medicare Limited.

Company profile and operating segment

Gujarat Themis Biosyn is described as manufacturing and marketing bulk drugs and intermediates, with a focus on fermentation-based APIs. Its product focus includes anti-tuberculosis and antibiotic products, serving both domestic and international pharmaceutical markets.

The company is also described as a small-cap pharmaceuticals company, with a cited market capitalisation of ₹4,404.38 crore in the provided text.

Key facts table

Market impact: what investors will watch next

The primary market-moving variable from here is the set of terms the company will disclose later, including the final issue size within the ₹1,000 crore cap, the security mix, the issue price, and the investor set for the QIP and preferential issue. The company has explicitly stated that these details will be decided by the committee and disclosed later.

Another item to watch is the sequence of approvals. The disclosures repeatedly note that the fundraising is subject to regulatory and statutory approvals, and the dividend payout is subject to shareholder approval at the forthcoming AGM. For investors, the timing of these clearances will influence when any issuance can occur.

Why the fundraising matters for the company

The fundraising decision comes alongside steps aimed at improving financial flexibility, including the shareholder-approved special resolutions to increase borrowing limits and expand inter-corporate investment capabilities. Taken together, these disclosures indicate the company is setting up multiple levers for funding and capital allocation.

Operationally, the company operates in bulk drugs and intermediates, with a stated focus on fermentation-based APIs used in anti-tuberculosis and antibiotic products. The disclosures in the provided text do not specify how the proceeds will be used, so the immediate focus remains on structure, pricing, and approvals.

Conclusion

Gujarat Themis Biosyn has approved raising up to ₹1,000 crore through a QIP and a preferential issue to non-promoters, with final terms to be decided by a committee and disclosed through subsequent filings. The next updates investors will watch are the issue structure, pricing, investor participation, and the timeline for regulatory and shareholder approvals.